Touchlight appoints SVP, Global Head of Sales
Curia expands biologics capabilities with access to Touchlight’s doggybone DNA
Touchlight launches its new customer offering of Discovery grade doggybone DNA (dbDNA)
Touchlight completes expansion, creating one of the world’s largest DNA manufacturing facilities in London, UK
20Med Therapeutics and Touchlight to collaborate on novel vaccine delivery platform project
Touchlight secures government grant to support its £14m investment in scale-up DNA manufacturing
Touchlight announces first FDA clearance of an IND utilising doggybone DNA
FDA accepts Drug Master File, signifying a new milestone for Touchlight’s enzymatic doggybone DNA technology
Touchlight and Odimma Therapeutics announce clinical material supply agreement to develop personalised cancer therapy utilising doggybone DNA
Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform
Touchlight signs license agreement with Voyager for use of Touchlight’s DNA technology in Voyager’s capsid discovery platform
Touchlight awarded Innovate UK grant for the measurement and intracellular visualisation of synthetic DNA constructs
mRNA-based therapeutics summit
Join us at the mRNA-based therapeutics summit in Boston, US (July 26-28, 2023).
Our team will be available to discuss your advanced therapy manufacturing. Learn how our enzymatically produced DNA vector called doggybone DNA (dbDNA) can significantly improve speed to manufacture, safety and scalability in comparison to plasmid DNA, for vaccine development.